Advertisement

Spontaneous and genetically engineered animal models

use in preclinical cancer drug development
  • K Hansen
    Affiliations
    Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA
    Search for articles by this author
  • C Khanna
    Correspondence
    Corresponding author. Tel.: +1-301-594-3406; fax: +1-301-402-4422
    Affiliations
    Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA
    Search for articles by this author

      Abstract

      The preclinical development of anticancer drugs has been based primarily on the transplantation of murine or human cancers into mice. Alternatives to these transplantation models are animals that naturally develop cancers with features relevant to the human disease. The first group of these models arises in mice that are genetically engineered to develop cancer. The second group includes pet dogs and cats that naturally develop cancer. This review will discuss the use and integration of these spontaneous cancer models into a comprehensive and comparative approach to preclinical drug development. Examples of their successful use and an outline of their relative strengths and weaknesses will be provided.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Van Dyke T
        • Jacks T
        Cancer modeling in the modern era.
        Cell. 2002; 108: 135-144
        • Leder A
        • Pattengale P.K
        • Kuo A
        • Stewart T.A
        • Leder P
        Consequences of widespread deregulation of the c-myc gene in transgenic mice.
        Cell. 1986; 45: 485-495
        • Johnstone R.W
        • Ruefli A.A
        • Lowe S.W
        Apoptosis.
        Cell. 2002; 108: 153-164
        • Clarke P
        • Mann J
        • Simpson J.F
        • Rickard-Dickson K
        • Primus F.J
        Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy.
        Cancer Res. 1998; 58: 1469-1477
        • Firat H
        • Garcia-Pons F
        • Tourdot S
        • et al.
        H-2 class I knockout, HLA-A2.1-transgenic mice.
        Eur. J. Immunol. 1999; 29: 3112-3121
        • Parangi S
        • O'Reilly M
        • Christofori G
        • et al.
        Antiangiogenic therapy of transgenic mice impairs de novo tumor growth.
        Proc. Natl. Acad. Sci. U.S.A. 1996; 93: 2002-2007
        • Donehower L.A
        • Harvey M
        • Slagle B.L
        • et al.
        Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.
        Nature. 1992; 356: 215-221
        • Yang M
        • Baranov E
        • Jiang P
        • et al.
        Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases.
        Proc. Natl. Acad. Sci. U.S.A. 2000; 97: 1206-1211
        • Diehn F.E
        • Costouros N.G
        • Miller M.S
        • et al.
        Noninvasive fluorescent imaging reliably estimates biomass in vivo.
        Biotechniques. 2002; 33 (,1254-1255): 1250-1252
        • Metz S
        • Daldrup-Unk H.E
        • Richter T
        • et al.
        Detection and quantification of breast tumor necrosis with MR imaging.
        Acad. Radiol. 2003; 10: 484-490
        • Pomper M.G
        Can small animal imaging accelerate drug development?.
        J. Cell Biochem. Suppl. 2002; 39: 211-220
        • Bergers G
        • Javaherian K
        • Lo K.M
        • Folkman J
        • Hanahan D
        Effects of angiogenesis inhibitors on multistage carcinogenesis in mice.
        Science. 1999; 284: 808-812
        • Shah K
        • Tang Y
        • Breakefield X
        • Weissleder R
        Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo.
        Oncogene. 2003; 22: 6865-6872
        • Omer C.A
        • Chen Z
        • Diehl R.E
        • et al.
        Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
        Cancer Res. 2000; 60: 2680-2688
        • Brown D
        • Kogan S
        • Lagasse E
        • et al.
        A PMLRARalpha transgene initiates murine acute promyelocytic leukemia.
        Proc. Natl. Acad. Sci. U.S.A. 1997; 94: 2551-2556
        • Al-Hajj M
        • Wicha M.S
        • Benito-Hernandez A
        • Morrison S.J
        • Clarke M.F
        Prospective identification of tumorigenic breast cancer cells.
        Proc. Natl. Acad. Sci. U.S.A. 2003; 100: 3983-3988
        • Khanna C
        • Vail D.M
        Targeting the lung.
        Curr. Cancer Drug Targets. 2003; 3: 265-273
        • Vail D.M
        • MacEwen E.G
        Spontaneously occurring tumors of companion animals as models for human cancer.
        Cancer Invest. 2000; 18: 781-792
        • Bronson R.T
        Variation in age at death of dogs of different sexes and breeds.
        Am. J. Vet. Res. 1982; 43: 2057-2059
        • Dorn C.R
        • Taylor D.O
        • Schneider R
        • Hibbard H.H
        • Klauber M.R
        Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County.
        J. Natl. Cancer Inst. 1968; 40: 307-318
        • Priester W.A
        • McKay F.W
        The occurrence of tumors in domestic animals.
        Natl. Cancer Inst. Monogr. 1980; 54: 1-210
        • Kelsey J.L
        • Moore A.S
        • Glickman L.T
        Epidemiologic studies of risk factors for cancer in pet dogs.
        Epidemiol. Rev. 1998; 20: 204-217
        • Khanna C
        • Wan X
        • Bose S
        • et al.
        The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis.
        Nat. Med. 2004; 10: 182-186
        • Lingaas F
        • Comstock K.E
        • Kirkness E.F
        • et al.
        A mutation in the canine BHD gene is associated with hereditary multifocal renal cystadenocarcinoma and nodular dermatofibrosis in the german shepherd dog.
        Hum. Mol. Genet. 2003;
        • Withrow S.J
        • MacEwen E.G
        Small Animal Clinical Oncology.
        3rd ed. W.B. Saunders Company, Philadelphia, PA2001
        • Phillips T.R
        • Billaud J.N
        • Henriksen S.J
        Methamphetamine and HIV-1.
        J. Psychopharmacol. 2000; 14: 244-250
        • Bogers W.M
        • Cheng-Mayer C
        • Montelaro R.C
        Developments in preclinical AIDS vaccine efficacy models.
        Aids. 2000; 14: S141-S151
        • Lutz T.A
        • Rand J.S
        A review of new developments in type 2 diabetes in human beings and cats.
        Br. Vet. J. 1993; 149: 527-536
        • Kirkness E.F
        • Bafna V
        • Halpern A.L
        • et al.
        The dog genome.
        Science. 2003; 301: 1898-1903
        • Higgins M.A
        • Berridge B.R
        • Mills B.J
        • et al.
        Gene expression analysis of the acute phase response using a canine microarray.
        Toxicol. Sci. 2003; 74: 470-484
        • Pennisi E
        Canine evolution. A shaggy dog history.
        Science. 2002; 298: 1540-1542
        • London C.A
        • Hannah A.L
        • Zadovoskaya R
        • et al.
        Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
        Clin. Cancer Res. 2003; 9: 2755-2768
        • Pryer N.K
        • Lee L.B
        • Zadovaskaya R
        • et al.
        Proof of target for SU11654.
        Clin. Cancer Res. 2003; 9: 5729-5734
        • Vail D.M
        • Kurzman I.D
        • Glawe P.C
        • et al.
        STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog.
        Cancer Chemother. Pharmacol. 2002; 50: 131-136
        • Dewhirst M.W
        Animal modeling and thermal dose.
        Radiol. Clin. North Am. 1989; 27: 509-518
        • Khanna C
        • Anderson P.M
        • Hasz D.E
        • Katsanis E
        • Neville M
        • Klausner J.S
        Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases.
        Cancer. 1997; 79: 1409-1421
        • Ladiges W.C
        • Storb R
        • Thomas E.D
        Canine models of bone marrow transplantation.
        Lab. Anim. Sci. 1990; 40: 11-15
        • Whelan H.T
        • Schmidt M.H
        • Segura A.D
        • et al.
        The role of photodynamic therapy in posterior fossa brain tumors. A preclinical study in a canine glioma model.
        J. Neurosurg. 1993; 79: 562-568
        • Dow S.W
        • Elmslie R.E
        • Willson A.P
        • Roche L
        • Gorman C
        • Potter T.A
        In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma.
        J. Clin. Invest. 1998; 101: 2406-2414
        • Withrow S.J
        • Thrall D.E
        • Straw R.C
        • et al.
        Intra-arterial cisplatin with or without radiation in limb-sparing for canine osteosarcoma.
        Cancer. 1993; 71: 2484-2490
        • Hershey A.E
        • Kurzman I.D
        • Forrest L.J
        • et al.
        Inhalation chemotherapy for macroscopic primary or metastatic lung tumors.
        Clin. Cancer Res. 1999; 5: 2653-2659
        • Skubitz K.M
        • Anderson P.M
        Inhalational interleukin-2 liposomes for pulmonary metastases.
        Anticancer Drugs. 2000; 11: 555-563
        • Rao R.D
        • Anderson P.M
        • Arndt C.A
        • Wettstein P.J
        • Markovic S.N
        Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) Therapy in metastatic cancer.
        Am. J. Clin. Oncol. 2003; 26: 493-498
        • Anderson P.M
        • Markovic S.N
        • Sloan J.A
        • et al.
        Aerosol granulocyte macrophage-colony stimulating factor.
        Clin. Cancer Res. 1999; 5: 2316-2323
        • Hogge G.S
        • Burkholder J.K
        • Culp J
        • et al.
        Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer.
        Hum. Gene Ther. 1998; 9: 1851-1861
        • Dickerson E.B
        • Fosmire S
        • Padilla M.L
        • Modiano J.F
        • Helfand S.C
        Potential to target dysregulated interleukin-2 receptor expression in canine lymphoid and hematopoietic malignancies as a model for human cancer.
        J. Immunother. 2002; 25: 36-45
        • Jarowenko D.G
        • Sigler S.C
        • Pellis N.R
        Muramyl tripeptide.
        J. Pediatr. Surg. 1987; 22: 497-500
        • Fidler I.J
        • Fan D
        • Ichinose Y
        Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma.
        Invasion Metastasis. 1989; 9: 75-88
        • Dinney C.P
        • Utsugi T
        • Fidler I.J
        • von Eschenbach A.C
        • Killion J.J
        Immunotherapy of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or gamma-interferon.
        Cancer Res. 1992; 52: 1155-1161
        • MacEwen E.G
        • Kurzman I.D
        • Helfand S
        • et al.
        Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors.
        J. Drug. Target. 1994; 2: 391-396
        • Vail D.M
        • MacEwen E.G
        • Kurzman I.D
        • et al.
        Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog.
        Clin. Cancer Res. 1995; 1: 1165-1170
        • Fox L.E
        • MacEwen E.G
        • Kurzman I.D
        • et al.
        Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma-a multicenter randomized double-blind study.
        Cancer Biother. 1995; 10: 125-130
        • Kurzman I.D
        • Shi F
        • Vail D.M
        • MacEwen E.G
        In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells.
        Cancer Biother. Radiopharm. 1999; 14: 121-128
        • Waters D.J
        High-grade prostatic intraepithelial neoplasia in dogs.
        Eur. Urol. 1999; 35: 456-458
        • Sorenmo K.U
        • Goldschmidt M
        • Shofer F
        • Goldkamp C
        • Ferracone J
        Immunohistochemical characterization of canine prostatic carcinoma and correlation with castration status and castration time.
        Journal of Veterinary and Comparative Oncology. 2003; 1: 48-56
        • Waters D.J
        • Shen S
        • Cooley D.M
        • et al.
        Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate.
        J. Natl. Cancer Inst. 2003; 95: 237-241
        • Khanna C
        • Prehn J
        • Hayden D
        • et al.
        A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma.
        Clin. Cancer Res. 2002; 8: 2406-2412
        • Guyon R
        • Lorentzen T.D
        • Hitte C
        • et al.
        A 1-Mb resolution radiation hybrid map of the canine genome.
        Proc. Natl. Acad. Sci. U.S.A. 2003; 100: 5296-5301
        • Hahn K.A
        • Bravo L
        • Adams W.H
        • Frazier D.L
        Naturally occurring tumors in dogs as comparative models for cancer therapy research.
        In Vivo. 1994; 8: 133-143
        • MacEwen E.G
        • Rosenthal R
        • Matus R
        • Viau A.T
        • Abuchowski A
        A preliminary study on the evaluation of asparaginase. Polyethylene glycol conjugate against canine malignant lymphoma.
        Cancer. 1987; 59: 2011-2015
        • MacEwen E.G
        • Rosenthal R.C
        • Fox L.E
        • Loar A.S
        • Kurzman I.D
        Evaluation of L-asparaginase.
        J. Vet. Intern. Med. 1992; 6: 230-234
        • Jeglum K.A
        • Young K.M
        • Barnsley K
        • Whereat A
        Chemotherapy versus chemotherapy with intralymphatic tumor cell vaccine in canine lymphoma.
        Cancer. 1988; 61: 2042-2050
      1. MacEwen EG, Hess PW, Hayes AA. A Clinical evaluation of the effectiveness of immunotherapy combined with chemotherapy for canine lymphosarcoma in the 8th symposium on comparative research on leukemia and related disease. 1977; Abstract: p. 162.

        • Sharpless N.E
        • Bardeesy N
        • Lee K.H
        • et al.
        Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.
        Nature. 2001; 413: 86-91
        • Groffen J
        • Voncken J.W
        • Kaartinen V
        • Morris C
        • Heisterkamp N
        Ph-positive leukemia.
        Leuk. Lymphoma. 1993; 11: 19-24
        • Reichert A
        • Heisterkamp N
        • Daley G.Q
        • Groffen J
        Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.
        Blood. 2001; 97: 1399-1403
        • Reitmair A.H
        • Schmits R
        • Ewel A
        • et al.
        MSH2 deficient mice are viable and susceptible to lymphoid tumours.
        Nat. Genet. 1995; 11: 64-70
        • Devita V.T
        • Hellman S
        • Rosenberg S.A
        Cancer: Principles and Practice of Oncology.
        6th ed. Lippincott, Williams, and Wilkins, Philadelphia, PA2001
        • Sohal J
        • Phan V.T
        • Chan P.V
        • et al.
        A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.
        Blood. 2003; 101: 3188-3197
        • Jacks T
        • Shih T.S
        • Schmitt E.M
        • Bronson R.T
        • Bernards A
        • Weinberg R.A
        Tumour predisposition in mice heterozygous for a targeted mutation in Nf1.
        Nat. Genet. 1994; 7: 353-361
        • Mahgoub N
        • Taylor B.R
        • Gratiot M
        • et al.
        In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells.
        Blood. 1999; 94: 2469-2476
        • Rego E.M
        • He L.Z
        • Warrell Jr., R.P
        • Wang Z.G
        • Pandolfi P.P
        Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
        Proc. Natl. Acad. Sci. U.S.A. 2000; 97: 10173-10178
        • He L.Z
        • Tolentino T
        • Grayson P
        • et al.
        Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.
        J. Clin. Invest. 2001; 108: 1321-1330
        • Corpet D.E
        • Pierre F
        Point.
        Cancer Epidemiol. Biomarkers Prev. 2003; 12: 391-400
        • Jacoby R.F
        • Seibert K
        • Cole C.E
        • Kelloff G
        • Lubet R.A
        The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
        Cancer Res. 2000; 60: 5040-5044
        • Huerta S
        • Arteaga J.R
        • Irwin R.W
        • Ikezoe T
        • Heber D
        • Koeffler H.P
        PC-SPES inhibits colon cancer growth in vitro and in vivo.
        Cancer Res. 2002; 62: 5204-5209
        • Quesada C.F
        • Kimata H
        • Mori M
        • Nishimura M
        • Tsuneyoshi T
        • Baba S
        Piroxicam and acarbose as chemopreventive agents for spontaneous intestinal adenomas in APC gene 1309 knockout mice.
        Jpn. J. Cancer Res. 1998; 89: 392-396
        • Kitamura T
        • Kawamori T
        • Uchiya N
        • et al.
        Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis.
        Carcinogenesis. 2002; 23: 1463-1466
        • Kitamura T
        • Itoh M
        • Noda T
        • et al.
        Combined effects of prostaglandin E receptor subtype EP(1) and subtype EP(4) antagonists on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice.
        Cancer Sci. 2003; 94: 618-621
        • Horig H
        • Wainstein A
        • Long L
        • et al.
        A new mouse model for evaluating the immunotherapy of human colorectal cancer.
        Cancer Res. 2001; 61: 8520-8526
        • Martiniello-Wilks R
        • Dane A
        • Mortensen E
        • Jeyakumar G
        • Wang X.Y
        • Russell P.J
        Application of the transgenic adenocarcinoma mouse prostate (TRAMP) model for pre-clinical therapeutic studies.
        Anticancer Res. 2003; 23: 2633-2642
        • Huss W.J
        • Barrios R.J
        • Greenberg N.M
        SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis.
        Mol. Cancer Ther. 2003; 2: 611-616
        • Perez-Stable C.M
        • Schwartz G.G
        • Farinas A
        • et al.
        The G gamma/T-15 transgenic mouse model of androgen-independent prostate cancer.
        Cancer Epidemiol. Biomarkers Prev. 2002; 11: 555-563
        • Green J.E
        • Shibata M.A
        • Shibata E
        • et al.
        2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
        Cancer Res. 2001; 61: 7449-7455
        • Jemal A
        • Murray T
        • Samuels A
        • Ghafoor A
        • Ward E
        • Thun M.J
        Cancer statistics, 2003.
        CA Cancer J. Clin. 2003; 53: 5-26
        • Ahern T.E
        • Bird R.C
        • Bird A.E
        • Wolfe L.G
        Expression of the oncogene c-erbB-2 in canine mammary cancers and tumor-derived cell lines.
        Am. J. Vet. Res. 1996; 57: 693-696
        • Parodi A.L
        • Misdorp W
        • Mialot J.P
        • et al.
        Intratumoral BCG and Corynebacterium parvum therapy of canine mammary tumours before radical mastectomy.
        Cancer Immunol. Immunother. 1983; 15: 172-177
        • Teske E
        • Rutteman G.R
        • vd Ingh T.S
        • van Noort R
        • Misdorp W
        Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE).
        Anticancer Res. 1998; 18: 1015-1019
        • Lombardi P
        • Florio S
        • Pagnini U
        • Crispino A
        • Avallone L
        Ovarian function suppression with a GnRH analogue.
        J. Vet. Pharmacol. Ther. 1999; 22: 56-61
        • Li B
        • Murphy K.L
        • Laucirica R
        • Kittrell F
        • Medina D
        • Rosen J.M
        A transgenic mouse model for mammary carcinogenesis.
        Oncogene. 1998; 16: 997-1007
        • Li M
        • Ren S
        • Tilli M.T
        • et al.
        Chemoprevention of mammary carcinogenesis in a transgenic mouse model by alpha-difluoromethylornithine (DFMO) in the diet is associated with decreased cyclin D1 activity.
        Oncogene. 2003; 22: 2568-2572
        • Kavanaugh C
        • Green J.E
        The use of genetically altered mice for breast cancer prevention studies.
        J. Nutr. 2003; 133: 2404S-2409S
        • Lobell R.B
        • Omer C.A
        • Abrams M.T
        • et al.
        Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
        Cancer Res. 2001; 61: 8758-8768
        • Muller W.J
        • Arteaga C.L
        • Muthuswamy S.K
        • et al.
        Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice.
        Mol. Cell. Biol. 1996; 16: 5726-5736
        • Lenferink A.E
        • Simpson J.F
        • Shawver L.K
        • Coffey R.J
        • Forbes J.T
        • Arteaga C.L
        Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu+MMTV/TGF-alpha bigenic mice.
        Proc. Natl. Acad. Sci. U.S.A. 2000; 97: 9609-9614
        • Guy C.T
        • Cardiff R.D
        • Muller W.J
        Induction of mammary tumors by expression of polyomavirus middle T oncogene.
        Mol. Cell. Biol. 1992; 12: 954-961
        • Muraoka R.S
        • Dumont N
        • Ritter C.A
        • et al.
        Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.
        J. Clin. Invest. 2002; 109: 1551-1559
        • Kraegel S.A
        • Gumerlock P.H
        • Dungworth D.L
        • Oreffo V.I
        • Madewell B.R
        K-ras activation in non-small cell lung cancer in the dog.
        Cancer Res. 1992; 52: 4724-4727
        • Vail D
        • Hershey A
        • Moore A
        Efficacy of adjuvant inhalational chemotherapy following surgical cytoreduction in dogs with spontaneously arising node positive primary lung cancer.
        Proc. Annu. Meet Am. Assoc. Cancer Res. 2000; (abstr 1272): 199
        • Wang Y
        • Zhang Z
        • Kastens E
        • Lubet R.A
        • You M
        Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression.
        Cancer Res. 2003; 63: 4389-4395
        • Zhang Z
        • Wang Y
        • Lantry L.E
        • et al.
        Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf.
        Oncogene. 2003; 22: 6257-6265
        • Sandmoller A
        • Halter R
        • Gomez-La-Hoz E
        • et al.
        The uteroglobin promoter targets expression of the SV40 T antigen to a variety of secretory epithelial cells in transgenic mice.
        Oncogene. 1994; 9: 2805-2815
        • Hoffman H.T
        • Karnell L.H
        • Funk G.F
        • Robinson R.A
        • Menck H.R
        The National Cancer Data Base report on cancer of the head and neck.
        Arch. Otolaryngol. Head Neck Surg. 1998; 124: 951-962
        • Walsh P
        • Gonzalez R
        • Dow S
        • et al.
        A phase I study using direct combination DNA injections for the immunotherapy of metastatic melanoma. University of Colorado Cancer Center Clinical Trial.
        Hum. Gene Ther. 2000; 11: 1355-1368
        • Lana S.E
        • Dernell W.S
        • LaRue S.M
        • et al.
        Slow release cisplatin combined with radiation for the treatment of canine nasal tumors.
        Vet. Radiol. Ultrasound. 1997; 38: 474-478
        • Opitz O.G
        • Harada H
        • Suliman Y
        • et al.
        A mouse model of human oral-esophageal cancer.
        J. Clin. Invest. 2002; 110: 761-769
        • Nishikawa T
        • Salim E.I
        • Morimura K
        • et al.
        High susceptibility of p53 knockout mice to esophageal and urinary bladder carcinogenesis induced by N, N-dibutylnitrosamine.
        Cancer Lett. 2003; 194: 45-54
        • Orian J.M
        • Tamakoshi K
        • Mackay I.R
        • Brandon M.R
        New murine model for hepatocellular carcinoma.
        J. Natl. Cancer Inst. 1990; 82: 393-398
        • Merle P
        • Barraud L
        • Lefrancois L
        • et al.
        Long-term high-dose interferon-alpha therapy delays Hepadnavirus-related hepatocarcinogenesis in X/myc transgenic mice.
        Oncogene. 2003; 22: 2762-2771
        • Dubois N
        • Bennoun M
        • Allemand I
        • et al.
        Time-course development of differentiated hepatocarcinoma and lung metastasis in transgenic mice.
        J. Hepatol. 1991; 13: 227-239
        • Baratin M
        • Ziol M
        • Romieu R
        • et al.
        Regression of primary hepatocarcinoma in cancer-prone transgenic mice by local interferon-gamma delivery is associated with macrophages recruitment and nitric oxide production.
        Cancer Gene Ther. 2001; 8: 193-202
        • Stubbs J.B
        • Frankel R.H
        • Schultz K
        • Crocker I
        • Dillehay D
        • Olson J.J
        Preclinical evaluation of a novel device for delivering brachytherapy to the margins of resected brain tumor cavities.
        J. Neurosurg. 2002; 96: 335-343
        • Thrall D.E
        • Larue S.M
        • Powers B.E
        • et al.
        Use of whole body hyperthermia as a method to heat inaccessible tumours uniformly.
        Int. J. Hyperthermia. 1999; 15: 383-398
        • Chauvet A.E
        • Kesava P.P
        • Goh C.S
        • Badie B
        Selective intraarterial gene delivery into a canine meningioma.
        J. Neurosurg. 1998; 88: 870-873
        • Goodrich L.V
        • Milenkovic L
        • Higgins K.M
        • Scott M.P
        Altered neural cell fates and medulloblastoma in mouse patched mutants.
        Science. 1997; 277: 1109-1113
        • Wetmore C
        • Eberhart D.E
        • Curran T
        Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched.
        Cancer Res. 2001; 61: 513-516
        • Weissenberger J
        • Steinbach J.P
        • Malin G
        • Spada S
        • Rulicke T
        • Aguzzi A
        Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice.
        Oncogene. 1997; 14: 2005-2013
        • Holland E.C
        A mouse model for glioma.
        Toxicol. Pathol. 2000; 28: 171-177
        • Yu A.S
        • Keeffe E.B
        Management of hepatocellular carcinoma.
        Rev. Gastroenterol. Disord. 2003; 3: 8-24
        • Glickman L.T
        • Schofer F.S
        • McKee L.J
        • Reif J.S
        • Goldschmidt M.H
        Epidemiologic study of insecticide exposures, obesity, and risk of bladder cancer in household dogs.
        J. Toxicol. Environ. Health. 1989; 28: 407-414
        • Chun R
        • Knapp D.W
        • Widmer W.R
        • et al.
        Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder.
        J. Vet. Intern. Med. 1997; 11: 279-283
        • Knapp D.W
        • Richardson R.C
        • Bottoms G.D
        • Teclaw R
        • Chan T.C
        Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors.
        Cancer Chemother. Pharmacol. 1992; 29: 214-218
        • Knapp D.W
        • Richardson R.C
        • Chan T.C
        • et al.
        Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder.
        J. Vet. Intern. Med. 1994; 8: 273-278
        • Knapp D.W
        • Glickman N.W
        • Widmer W.R
        • et al.
        Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer.
        Cancer Chemother. Pharmacol. 2000; 46: 221-226
        • Nseyo U.O
        • Whalen R.K
        • Lundahl S.L
        Canine bladder response to red and green light whole bladder photodynamic therapy.
        Urology. 1993; 41: 392-396
        • Bex A
        • Vooijs M
        • Horenblas S
        • Berns A
        Controlling gene expression in the urothelium using transgenic mice with inducible bladder specific Cre-lox recombination.
        J. Urol. 2002; 168: 2641-2644
        • Cheng J
        • Huang H
        • Pak J
        • et al.
        Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder.
        Cancer Res. 2003; 63: 179-185
        • Grippo P.J
        • Sandgren E.P
        Highly invasive transitional cell carcinoma of the bladder in a simian virus 40 T-antigen transgenic mouse model.
        Am. J. Pathol. 2000; 157: 805-813
        • Bergers G
        • Brekken R
        • McMahon G
        • et al.
        Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis.
        Nat. Cell Biol. 2000; 2: 737-744
        • Man S
        • Bocci G
        • Francia G
        • et al.
        Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
        Cancer Res. 2002; 62: 2731-2735
        • Withrow S.J
        • Powers B.E
        • Straw R.C
        • Wilkins R.M
        Comparative aspects of osteosarcoma. Dog versus man.
        Clin. Orthop. 1991; 270: 159-168
        • Straw R.C
        • Withrow S.J
        Limb-sparing surgery versus amputation for dogs with bone tumors.
        Vet. Clin. North Am. Small Anim. Pract. 1996; 26: 135-143
        • MacEwen E.G
        • Kurzman I.D
        • Rosenthal R.C
        • et al.
        Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide.
        J. Natl. Cancer Inst. 1989; 81: 935-938
        • Kurzman I.D
        • MacEwen E.G
        • Rosenthal R.C
        • et al.
        Adjuvant therapy for osteosarcoma in dogs.
        Clin. Cancer Res. 1995; 1: 1595-1601
        • Bergman P.J
        • MacEwen E.G
        • Kurzman I.D
        • et al.
        Amputation and carboplatin for treatment of dogs with osteosarcoma.
        J. Vet. Intern. Med. 1996; 10: 76-81
        • Straw R.C
        • Withrow S.J
        • Douple E.B
        • et al.
        Effects of cis-diamminedichloroplatinum II released from D,L-polylactic acid implanted adjacent to cortical allografts in dogs.
        J. Orthop. Res. 1994; 12: 871-877
        • Alexander J
        Use of transgenic mice in identifying chemopreventive agents.
        Toxicol. Lett. 2000; 112-113: 507-512
        • Hursting S.D
        • Perkins S.N
        • Haines D.C
        • Ward J.M
        • Phang J.M
        Chemoprevention of spontaneous tumorigenesis in p53-knockout mice.
        Cancer Res. 1995; 55: 3949-3953
        • Marton I
        • Johnson S.E
        • Damjanov I
        • Currier K.S
        • Sundberg J.P
        • Knowles B.B
        Expression and immune recognition of SV40 Tag in transgenic mice that develop metastatic osteosarcomas.
        Transgenic. Res. 2000; 9: 115-125
        • Wilkie T.M
        • Schmidt R.A
        • Baetscher M
        • Messing A
        Smooth muscle and bone neoplasms in transgenic mice expressing SV40 T antigen.
        Oncogene. 1994; 9: 2889-2895
        • Gillette S.M
        • Dewhirst M.W
        • Gillette E.L
        • et al.
        Response of canine soft tissue sarcomas to radiation or radiation plus hyperthermia.
        Int. J. Hyperthermia. 1992; 8: 309-320
        • Dernell W.S
        • Withrow S.J
        • Straw R.C
        • Powers B.E
        • Drekke J.H
        • Lafferty M
        Intracavitary treatment of soft tissue sarcomas in dogs using cisplatin in a biodegradable polymer.
        Anticancer Res. 1997; 17: 4499-4505
        • Jhappan C
        • Noonan F.P
        • Merlino G
        Ultraviolet radiation and cutaneous malignant melanoma.
        Oncogene. 2003; 22: 3099-3112
        • Bergman P.J
        • McKnight J
        • Novosad A
        • et al.
        Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase.
        Clin. Cancer Res. 2003; 9: 1284-1290
        • Otsuka T
        • Takayama H
        • Sharp R
        • et al.
        c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype.
        Cancer Res. 1998; 58: 5157-5167
        • Zhu H
        • Reuhl K
        • Zhang X
        • et al.
        Development of heritable melanoma in transgenic mice.
        J. Invest. Dermatol. 1998; 110: 247-252
        • Noonan F.P
        • Otsuka T
        • Bang S
        • Anver M.R
        • Merlino G
        Accelerated ultraviolet radiation-induced carcinogenesis in hepatocyte growth factor/scatter factor transgenic mice.
        Cancer Res. 2000; 60: 3738-3743